Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Investorideas.com highlights advancements in blood purification medical devices, focusing on Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The global blood purification market is projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030. Aethlon plans Phase 1 trials in Australia and India for patients with stable or progressive solid tumors not responding to anti-PD-1 therapies. The Hemopurifier® aims to remove cancer-promoting exosomes and viruses. The FDA has designated it a 'Breakthrough Device' for specific cancers and viral infections. Data from recent in vitro studies support its efficacy in removing extracellular vesicles from cancer patient plasma, facilitating further clinical trials.
Aethlon Medical is advancing its phase 1 clinical trials for the Hemopurifier®, aimed at patients with solid tumors unresponsive to anti-PD-1 treatments like Keytruda® or Opdivo®.
Progress includes the integration of new in vitro data showing exosome removal from cancer patient plasma, which has been included in documentation for Ethics Committees. Submissions have been made to Ethics Boards in Australia and India, with one site already submitting on May 24, 2024.
Once approvals are received, Clinical Trial Agreements will be finalized, and patient recruitment can begin. The trials focus on safety, feasibility, and dose-finding.
Aethlon Medical (Nasdaq: AEMD), a therapeutic company specializing in cancer and infectious disease treatments, announced a public offering priced at $0.58 per share. This includes 8,100,000 common shares, Class A and Class B warrants to purchase up to 8,100,000 shares each. The Class A warrants expire in five years and Class B in one year. Gross proceeds are expected to be $4.7 million before expenses, with funds directed towards clinical trials, R&D, capital expenditures, and working capital. Closing is anticipated by May 17, 2024. Maxim Group is the exclusive placement agent.
Aethlon Medical, Inc. reported positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from cancer patient plasma. The study supports the design of a Phase 1 trial in cancer patients with solid tumors undergoing anti-PD-1 treatment. The Hemopurifier showed promise in reducing EVs from plasma, paving the way for upcoming clinical trials in Australia and India.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.